Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Chronic Low Back Pain

Eli Lilly and Company33 sites in 2 countries153 target enrollmentMay 20, 2021

ConditionsChronic Low-back Pain

InterventionsLY3556050 Placebo

DrugsLY3556050 Placebo

Overview

Phase: Phase 2
Intervention: LY3556050
Conditions: Chronic Low-back Pain
Sponsor: Eli Lilly and Company
Enrollment: 153
Locations: 33
Primary Endpoint: Change From Baseline for Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This study is being done to test the safety and efficacy of the study drug LY3556050 for the treatment of chronic low back pain. This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.

Registry

clinicaltrials.gov

Start Date

May 20, 2021

End Date

February 9, 2022

Last Updated

2 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Eli Lilly and Company

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Have a visual analog scale (VAS) pain value ≥40 and \<95 during screening.
•Have a history of daily pain for at least 12 weeks based on participant report or medical history.
•Have a value of ≤30 on the pain catastrophizing scale.
•Have a body mass index \<40 kilograms per meter squared (kg/m²) (inclusive).
•Are willing to maintain a consistent regimen of any ongoing nonpharmacologic pain-relieving therapies (for example, physical therapy) and will not start any new nonpharmacologic pain-relieving therapies during study participation.
•Are willing to discontinue all medications taken for chronic pain conditions for the duration of the study.
•Have a history of low back pain for at least 3 months located between the 12th thoracic vertebra and the lower gluteal folds, with or without radiation.
•Have a history of low back pain as classified by the Quebec Task Force Category 1 through
•Have stable glycemic control as indicated by a glycated hemoglobin (HbA1c) less than or equal to 10 at time of screening.
•Are men, or women able to abide by reproductive and contraceptive requirements.

Exclusion Criteria

•Have second or third-degree atrioventricular (AV) heart block or AV dissociation or history of ventricular tachycardia.
•Have had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest (for example, ablation techniques).
•Have surgery planned during the study for any reason, related or not to the disease state under evaluation.
•Have, in the judgment of the investigator, an acute, serious, or unstable medical condition or a history or presence of any other medical illness that would preclude study participation.
•There is an inability to rule out other causative or confounding sources of pain in the primary condition under study.
•Have had cancer within 2 years of baseline, except for cutaneous basal cell or squamous cell carcinoma resolved by excision.
•Have a substance use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (5th edition; DSM-5; American Psychiatric Association).
•Have congenital QT prolongation or QT interval corrected for heart rate using Fridericia's formula (QTcF) interval measurement \>450 milliseconds (msec) for male participants, \>470 msec for female participants, or \>480 msec for participants with bundle branch block.
•Have any clinically important abnormality at screening, as determined by investigator, in physical or neurological examination, vital signs, electrocardiogram (ECG), or clinical laboratory test results that could be detrimental to the participant or could compromise the study.
•Have a positive human immunodeficiency virus (HIV) test result at screening.

Arms & Interventions

600 Milligram (mg) LY3556050

Participants received 600 mg LY3556050 twice daily (BID) every 12 hours for up to 8 weeks.

Intervention: LY3556050

Placebo

Participants received placebo BID every 12 hours for up to 8 weeks.

Intervention: Placebo

Outcomes

Primary Outcomes

Change From Baseline for Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)

Time Frame: Baseline, Week 8

The NRS was used to describe pain severity. Participants were asked to describe their average pain over the past 24 hours, on a scale of 0 to 10: 0 = no pain, and 10 = pain as bad as you can imagine. Posterior mean change from baseline, 95 percent (%) credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval.

Secondary Outcomes

Change From Baseline for Worst Pain Intensity as Measured by NRS(Baseline, Week 8)
Change From Baseline on the EuroQuality of Life Five Dimensions (5D) Five Level (5L) Questionnaire (EQ-5D-5L) Health State Index (United States Algorithm)(Baseline, Week 8)
Change From Baseline on the Roland Morris Disability Questionnaire (RMDQ)(Baseline, Week 8)
Change From Baseline for Overall Improvement as Measured by Patient's Global Impression of Change(Baseline, Week 8)
Change From Baseline on the Visual Analog Scale (VAS) for Pain(Baseline, Week 8)
Change From Baseline on the Sleep Scale From the Medical Outcomes Study (MOS Sleep Scale) - Average Hours of Sleep(Baseline, Week 8)
Total Amount of Rescue Medication Use as Measured by Average Daily Dosage(Week 8)